An in vitro versus in vivo toxicogenomics investigation of prenatal exposures to tobacco smoke by Perry, Iain et al.
This is an Open Access document downloaded from ORCA, Cardiff University's institutional
repository: http://orca.cf.ac.uk/98751/
This is the author’s version of a work that was submitted to / accepted for publication.
Citation for final published version:
Perry, Iain, Sexton, Keith, Prytherch, Zoe, Jason, Blum, Judith, Zelikoff and Berube, Kelly 2017. An
in vitro versus in vivo toxicogenomics investigation of pre-natal exposures to tobacco smoke.
Applied In Vitro Toxicology 10.1089/aivt.2016.0041 file 
Publishers page: https://doi.org/10.1089/aivt.2016.0041 <https://doi.org/10.1089/aivt.2016.0041>
Please note: 
Changes made as a result of publishing processes such as copy-editing, formatting and page
numbers may not be reflected in this version. For the definitive version of this publication, please
refer to the published source. You are advised to consult the publisher’s version if you wish to cite
this paper.
This version is being made available in accordance with publisher policies. See 
http://orca.cf.ac.uk/policies.html for usage policies. Copyright and moral rights for publications
made available in ORCA are retained by the copyright holders.
 An In Vitro Versus In Vivo Toxicogenomics Investigation of Pre-natal Exposures 
to Tobacco Smoke 
 
Iain Perry1, Keith Sexton1, Zoe Prytherch1, Jason Blum2, Judith Zelikoff2* and Kelly Ann 
BéruBé1* 
 
1School of Biosciences, Cardiff University, Museum Avenue, Cardiff, CF10 3AX, UK. 
2Department Environmental Medicine, NYU School of Medicine, NYU Langone Medical Centre, 57 Old Forge 
Road, Tuxedo, NY 10987, USA 
 
*Joint Corresponding Authors 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abstract 
Approximately 1 million women smoke during pregnancy despite evidence demonstrating serious juvenile and/or 
adult diseases being linked to early-life exposure to cigarette smoke. Susceptibility could be determined by factors in 
previous generations, i.e. pre-natal or ‘maternal’ exposures to toxins. Pre-natal exposure to airborne pollutants such 
as mainstream cigarette smoke has been shown to induce early-life insults (i.e. gene changes) in Offspring that serve 
as biomarkers for disease later in life. In this investigation, we have evaluated genome-wide changes in the lungs of 
mouse Dams and their juvenile Offspring exposed pre-natally to mainstream cigarette smoke.  An additional lung 
model was tested alongside the murine model, as a means to find an alternative in vitro, human tissue-based 
replacement for the use of animals in medical research. Our toxicogenomic and bioinformatic results indicated that in 
utero exposure altered the genetic patterns of the foetus that could put them at greater risk for developing a range of 
chronic illnesses in later-life. The genes altered in the in vitro, cell culture model were reflected in the murine model 
of pre-natal exposure to MCS. The use of alternative in vitro models derived from human medical waste tissues could 
be viable options to achieve human end-point data and to conduct research that meets the remits for scientists to 
undertake the 3Rs practises.  
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Introduction
Lung cancer was estimated to have accounted for over 14% of cancer cases in the US during 2014 and more than 27% 
of cancer related mortalities. Indeed, nearly 70% of incidences of lung cancer are predicted to end in mortality (Siegel 
et al. 2014).  Despite the high incidence and mortality rates, lung cancer has historically received a disproportionately 
low share of funding for research. The US National Institute of Health calculated the US spent less than 5% of all cancer 
research funding on dedicated lung cancer research (NIH, 2015). The imbalance of research funding in the US is 
indicative of a wider global trend, which is often attributed to the wider social stigma that lung cancer is a direct result 
of smoking and the consequence of their conscious transgressions. Indeed, the complex mixture of over 4000 cigarette 
smoke compounds, of which many either direct or second-hand, are known to have direct links to, cancer, cell irritation 
and death (Ng et al. 2006, Faux et al. 2009, Doherty et al. 2009). Yet, despite this around 25% of cases of lung cancer 
are not being directly linked to smoking (Sun et al. 2007). Second hand cigarette smoke, air pollution, inhalation of 
carcinogens and hereditary genes are all known to increase risk of developing lung cancer (Samet et al. 2009). These 
all also contribute to the multiple respiratory diseases burdening health worldwide (Bousquet, Khaltaev and Cruz, 
2007). Chronic obstructive pulmonary disease (COPD), respiratory tract infections, pneumonia and asthma, all 
contribute to increasing financial cost and strain on medical care with COPD prevalence as high as 9% in some US 
states (CDC, 2014). 
The lack of progress in lung cancer therapeutics combined with international goals for replacement, reduction and 
refinement (i.e. 3Rs; Russell and Burch, 1959) of animal testing (APC, 2003), is a driving need to shift towards 
alternative models (BéruBé et al. 2011; BéruBé, 2013). These alternative models have historically been limited to 
monolayer cultures of specific cell lines, which fail to account for the intricacy and real world variability offered through 
animal testing (Kroll et al. 2009). However, a complication associated with in vivo testing arises from intra-subject 
variation of immune responses, which is often activated by foreign object particulates or pathogens (Cressler et al. 
2014). Use of in vitro testing can, as such, simplify understanding of pathological pathways to the route mechanism 
and is particularly useful in multi-stimuli studies. 
Only in recent years have there been advances in the growth of complex tissues capable of providing the intermediary 
between simple in vitro cell monolayers and complex in vivo animal models (Bredenkamp et al. 2014). Laboratory 
grown models reduce the burden on animal testing, allowing for multiple cell-type interactions to be examined 
without the more confounding aspects resulting from the presence of systemic systems and the immune response. 
Furthermore, the ability to test multiple cell type response using human tissues, negating the reliance on use of 
alternative species as models, provides more ethically and biologically relevant research into the carcinogenic and 
damaging effects of inhaled toxicants such as cigarette smoke and air pollution (Adam et al. 2015). MatTek’s 
EpiAirway® is a multi-cellular, differentiated model of the human bronchial epithelium derived from healthy human 
primary tracheo-bronchial cells. The model is aimed at replicating the epithelial tissue of the human respiratory tract 
(BéruBé et al. 2009; Prytherch and BéruBé, 2014). 
This study was aimed at confirming, through transcriptomics, the suitability of a laboratory grown human lung model 
(EpiAirway®) as an alternative model to study the genetic effects on gene regulation and associated pathways caused 
from tobacco smoke inhalation (Balharry et al. 2008; Sexton et al. 2008; Sexton et al. 2011). The study also aimed to 
look at the downstream implications on offspring carried during exposure. The EpiAirway® model and pregnant female 
mice were exposed to mainstream cigarette smoke (MCS) or filtered air before lung tissue RNA extraction and gene 
regulation were assessed via the Agilent Single Colour Microarray (Agilent, 2015). 
  
Materials and methods  
In vitro cell culture exposures
The EpiAirway cell cultures were transported from MatTek in the USA in a 24-well plate format. The cells were 
equilibrated at 37°C with 4.5% CO2 for 24 h following manufacturer’s guidelines. Culture pre-conditioning, acute 
exposure (24 h) of the EpiAirway lung tissue (ELT) to mainstream cigarette smoke (MCS) was carried out at the air-
liquid interface (ALI) as per the methods by Sexton, Balharry and co-workers (2008), respectively. Each insert had a 
surface area of 1 cm2 and was apically dosed.  
 
Animal exposures
Mainstream Cigarette Smoke was generated through burning 3R4F reference filtered cigarettes (Kentucky Tobacco 
Research and Development Centre, Lexington, KY) on an automated CS generation system (Baumgartner-Jaeger CSM 
2070; CH Technologies Inc., Westwood, NJ) and both Dams and EpiAirway® lung tissue cultures were exposed as 
described in Ng et al. (2006). Smoke was drawn from the cigarettes under ISO standard conditions (35 ml puff drawn 
over 2 seconds every 1 minute) and diluted in filtered air using an RM20s smoke engine (Borgwaldt Technik GmbH, 
Hamburg, Germany). Diluted smoke (1/50 smoke:air v/v) was continually delivered to exposure chambers (UK patent 
number WO 03/100417 A1) containing the culture inserts for a period of 1 hr. Exposure was designed to be equivalent 
to an adult human smoking ~10 cigarettes/day for 18 consecutive days. In the absence of cells, the total deposition of 
particulates on the base of the cell culture inserts was determined to be 1.84 μg/cm2. We generated 1 mg/m3 for the 
cell culture studies. For our cigarette smoke animal studies, we exposed 4 hr/d running a continuous 15 mg/m3 
concentration in the chamber. B6C6F1 mice (Jackson Laboratory, Bar Harbor, ME) were acclimatised and mated as 
described in Ng et al. (2006). Pregnant females (Dams) were exposed to MCS (or filtered air) via whole body inhalation 
4 hours/day for 5 days/week during gestation until parturition (18 days) and sacrificed post-exposure and the Dams’ 
and the Offspring’ lungs (n = 3 replicates each) were extracted. EpiAirway® lung tissue (ELT; n = 3 replicates) was 
exposed to the same level of MCS (or filtered air) and for the same duration. Lungs were preserved in RNAlater (Qiagen, 
USA) for genomic analysis at Cardiff University (Wales).  
 
Sample preparation
Total RNA was extracted and purified from Dam and ELT tissues using RNeasy Mini Kit, (Qiagen, UK). Purity and 
integrity of extracted RNA was assessed using an Agilent 2100 BioAnalyzer (Agilent Technologies, Palo Alto, CA, USA). 
Five hundred ng of total RNA from each of the lung tissue samples and the Universal Human/mouse Reference RNA 
(Stratagene, La Jolla, CA, USA) was used for amplification or RNA and labelling with cyanine (Cy) 5 (experimental 
samples) or Cy 3 (reference) using the Agilent's Low RNA Input Linear Amplification Kit (Agilent Technologies) according 
to the manufacturer’s instructions.  Labelled samples and reference cRNAs were purified using RNeasy mini spin 
columns (Qiagen, UK) and eluted in 30 μl of nuclease-free water. After amplification and labelling, cRNA quantity and 
Cy dye incorporation were determined using a Nanodrop ND.1000 UV-VIS-Spectrophotometer version 3.2.1 (Agilent 
Technologies).  For each hybridisation, 1 μg Cy 3 labelled cRNA (reference) and 1 μg of Cy 5 labelled cRNA (samples) 
were mixed, fragmented, and hybridized at 65°C for 17 hours onto Agilent Whole human/mouse genome 4×44 K 
60mer Oligo Microarrays.  Labelled cRNA from three different ELT, Dams or Offspring tissues were each hybridized to 
the arrays. After washing, microarrays were scanned using an Agilent Array scanner (G2505C) (Agilent Technologies) 
and the images were analysed. Reproducibility and reliability of each single microarray was assessed using Quality 
Control report data. Data were extracted using Agilent feature extraction software (version 9.5.3) and the GE2-
v5_95_Feb07 protocol. Additionally, genes with either uniformly low expression or low expression variation across the 
experiments were eliminated. 
Analysing gene expression
Microarray data was analysed using GeneSpring (version 13.0) to highlight differentially expressed genes. Samples 
were grouped by exposure to MCS and filtered air for the Dams, Offspring and the ELT, normalising the arrays to the 
75th percentile. Quality control on each data set was performed to minimise false detection rate. A moderated T-Test 
used a cut off p-value value of 0.05 and minimum 1.4 fold change without false detection rate (FDR). These values 
were chosen as Dalman et al. (2011) concluded that lower fold change cut-off produces more significant results in 
gene ontology (GO). Up and down regulated genes which satisfied these criteria underwent gene enrichment analysis. 
FDR was accounted for through the use of Gene enrichment of DAVID’s Benjamini-Hochberg score for corrected P-
value, rather than through the use of Bonferroni style approaches at earlier stages which, while reducing false 
positives, often simultaneously exclude true positives. GO-terms and significant pathways for the up and down 
regulated genes were identified through the use of DAVID (version 6.7) (Huang et al. 2009a; Huang et al. 2009b) and 
strength of association assessed though p-value and Benjamini score, where Gene ontology was deconstructed by 
biological process using REVIGO (Supek et al. 2011) with an allowed similarity of 0.7 and visualised using Cytoscape 
(version 3.2.1) (Shannon et al. 2002).   
 
Results 
Following normalisation and quality control, 27758, 26571 and 25250 out of 44,000 features were retained for the 
ELT, Dams and Offspring respectively. Following a moderated T-Test with p-value 0.05 cut-off and minimum 1.4 fold 
change; 716 (500 up-regulated, 216 down-regulate) genes in the ELT, 437 (283 up-regulated, 154 down-regulated) 
genes in the Dams and 9825 (5208 up-regulated, 4617 down-regulated) genes in the Offspring were identified as 
significantly altered, comparing exposure of MCS and filtered air (Figure 1).  The top 10 differentially (up and down) 
expressed genes for the ELT, Dams and Offspring were identified and listed in the Supplemental Table 1.  
 
Figure 1. Selection of differentially expressed genes of ELT tissue (A) Dam lung tissue (B) and Offspring lung tissue 
(C). Volcano plot of differentially expressed genes between ELT, Dams and Offspring tissues exposed to CMS and 
filtered air. The vertical lines correspond to 1.4-fold up and down expression and the horizontal line represents a p-
value of 0.05.  
Of the top up-regulated genes in ELT, many have direct functions in regulation and cell adhesion [C-FOS], cell division 
[CDC20B] and matrix proteins [MATN1], while the top ELT down-regulated genes have links to cell binding [FN1], 
calcium/zinc ion binding in proteolysis [MMP12] and calcium ion binding in protease inhibition [SPOCK1]. The Dams 
top up-regulated genes, most have direct functions in immunity, (e.g. Ighg – Immunoglobulin heavy constant-γ), but 
also includes killer cell lectin-like receptors [KLRA17] and Mediterranean fever [MEFV], with the top Dam down-
regulated genes have links to fat regulation and cell life regulation [RETN], regulation of lipid biosynthetic process 
[THRSP] and mucus production [MUC5B]. The top Offspring up-regulated gene have functions in histocompatibility, 
[H2AB1], haemoglobin [HBB-BT] and immunity [LY6D]) and the top Offspring down-regulated genes have links to 
chloride ion channels [BEST1], Tight junctions [TJP2] and GTPases [AGAP1].  
The genes that saw the greatest fold change in expression give an indication into large gene network pathways and 
therefore, gene ontology was performed to see what the global trends in gene regulation of the cell were involved. 
Up and down regulated genes underwent GO analysis through DAVID and the top 10 enriched terms for the genes 
associated with, biological process (BP), cellular component (CC) and molecular function (MF) were identified (Table 
1).  
  
Table 1. Top 10 Enrichment terms extracted from DAVID. 
 
 Term P Value  Term P Value  Term P Value 
E
LT
 B
P
 
Microtubule-Based 
Movement 
Microtubule-Based 
Process 
Cellular 
Developmental 
Process 
Ciliary Or Flagellar 
Motility 
Ectoderm 
Development 
Developmental 
Process 
Multicellular 
Organismal Process 
Cell Differentiation 
Epidermis 
Development 
Tissue Development 
8.60E-09 
 
2.31E-06 
 
7.30E-06 
 
 
1.17E-05 
 
1.94E-05 
 
2.70E-05 
 
5.30E-05 
 
9.25E-05 
1.16E-04 
 
2.23E-04 D
a
m
s 
B
P
 
Immune Response 
Immune System 
Process 
Response To External 
Stimulus 
Response To Stimulus 
Nuclear Division 
Mitosis 
M Phase Of Mitotic 
Cell Cycle 
Organelle Fission 
Cell Division 
Chemotaxis 
6.70E-19 
9.00E-16 
 
4.09E-09 
 
7.60E-09 
9.73E-09 
9.73E-09 
1.35E-08 
 
1.72E-08 
3.80E-08 
7.76E-08 
O
ff
sp
ri
n
g
 B
P
 
Cellular Process 
Cellular Metabolic 
Process 
Cellular  Metabolic 
Process 
Metabolic Process 
Macromolecule 
Metabolic Process 
Primary Metabolic 
Process 
Cellular Protein 
Metabolic Process 
Gene Expression 
Protein Metabolic 
Process 
Cellular Component 
Organization 
1.23E-91 
1.30E-52 
 
1.86E-43 
 
2.31E-41 
1.82E-35 
 
9.05E-35 
 
8.79E-34 
 
1.64E-25 
5.00E-23 
 
1.53E-21 
E
LT
 C
C
 
Cytoskeleton 
Cilium 
Axoneme 
Cell Projection 
Cytoskeletal Part 
Microtubule 
Microtubule 
Cytoskeleton 
Microtubule 
Associated Complex 
Cell Projection Part 
Dynein Complex 
1.36E-14 
3.87E-11 
1.47E-10 
2.06E-10 
2.08E-10 
6.81E-10 
6.29E-09 
2.32E-08 
6.26E-08 
 
8.15E-08 
D
a
m
s 
C
C
 
Cell Surface 
External Side Of 
Plasma Membrane 
Extracellular Space 
Chromosome, 
Centromeric Region 
Extracellular Region 
Part 
Condensed 
Chromosome, 
Centromeric Region 
Condensed 
Chromosome 
Kinetochore 
Extracellular Region 
Chromosomal Part 
Kinetochore 
4.25E-10 
1.37E-09 
 
7.40E-08 
9.11E-07 
 
2.18E-06 
 
1.31E-05 
 
 
4.88E-05 
 
 
5.70E-05 
8.49E-05 
1.35E-04 O
ff
sp
ri
n
g
 C
C
 
Intracellular 
Intracellular Part 
Cytoplasm 
Organelle 
Intracellular Organelle 
Membrane-Bounded 
Organelle 
Intracellular 
Membrane-Bounded 
Organelle 
Cytoplasmic Part 
Intracellular Organelle 
Part 
Organelle Part 
3.90E-135 
4.56E-124 
5.02E-96 
8.86E-83 
1.40E-82 
7.70E-59 
 
1.33E-58 
 
 
1.25E-52 
8.85E-38 
 
7.09E-37 
E
LT
 M
F
 
Microtubule Motor 
Activity 
Structural Molecule 
Activity 
Motor Activity 
Metalloendopeptidase 
Activity 
Metallopeptidase 
Activity 
Calcium Ion Binding 
Structural Constituent 
Of Cytoskeleton 
Nucleoside-
Triphosphatase 
Activity 
Extracellular Matrix 
Structural Constituent 
Pyrophosphatase 
Activity 
4.25E-09 
 
2.94E-07 
 
3.72E-07 
4.56E-05 
 
1.60E-04 
 
2.67E-04 
4.27E-04 
 
0.003537 
 
 
0.004979 
 
0.006094 
D
a
m
s 
M
F
 
Sugar Binding 
Carbohydrate Binding 
Chemokine Activity 
Chemokine Receptor 
Binding 
Cytokine Activity 
Receptor Binding 
Sh3/Sh2 Adaptor 
Activity 
Signal Transducer 
Activity 
Molecular Transducer 
Activity 
Protein Binding 
2.08E-11 
2.15E-10 
5.32E-06 
6.39E-06 
 
6.58E-06 
6.38E-05 
2.26E-04 
 
2.34E-04 
 
2.34E-04 
 
2.89E-04 
O
ff
sp
ri
n
g
 M
F
 
Binding 
Protein Binding 
Structural Constituent 
Of Ribosome 
Cytoskeletal Protein 
Binding 
Catalytic Activity 
Purine Ribonucleotide 
Binding 
Ribonucleotide 
Binding 
Purine Nucleotide 
Binding 
Actin Binding 
Nucleotide Binding 
1.21E-65 
8.57E-42 
2.72E-26 
 
2.27E-16 
 
1.04E-14 
3.90E-14 
 
3.90E-14 
 
1.13E-13 
 
1.25E-13 
2.24E-13 
 
 
 
 
DAVID ranks associated genes with a GO term to provide an enrichment score, with highly enriched terms have a 
greater number of associated genes. Many of the top 10 BPs, MFs and all the CCs for ELT relate to cytoskeletal genes 
and cell development. The Dams had BPs relating to cell cycle and additionally significant immune response 
alterations. The CCs identified were mostly involved with the chromosomal organisation while MFs had highly enriched 
terms in receptor binding and transmission. This suggested that ELT was primarily affected in cellular organisation 
while the Dams were primarily responding to external stimuli, above a cellular organisation response. To investigate 
similarities in response, common GO terms between ELT and the Dams were collated. Offspring had many GO terms 
associated with metabolic processes, organelle structure and protein binding.  
To assess the similarities between ELT as a model for replacement of the Dams, common processes for all GO-terms 
for ELT and Dams were identified (Table 2). The common terms can largely be linked to the processes of cellular 
adhesion and response to a stimulus. This indicated the Dams immune response was masking similar mechanical 
pathway changes with the ELT. The global KEGG pathways identified through DAVID display the complexity of the 
Dams when compared to the ELT (Table 3). ELT tissues highlight 5 pathways, including ECM-receptor interactions and 
pathways in cancer and cardiac stress. Dam tissue had a large range of 19 disease pathways altered that included 
immunity, cell cycle regulation, diabetes and cell adhesion. The Offspring however showed a vast network of 61 
disease and cancer pathways which included Alzheimer’s and Parkinson’s, Chronic myeloid leukaemia, Colorectal 
cancer and Type II diabetes. 
 
Table 2. Common GO terms found between ELT and Dams. 
GO term Description ELT P-value Dams P-value 
GO:0044421 Extracellular region part 3.41E-06 2.18E-06 
GO:0005576 Extracellular region 8.30E-05 5.70E-05 
GO:0005615 Extracellular space 6.59E-04 7.40E-08 
GO:0005488 Binding 2.16E-02 1.70E-03 
GO:0044459 Plasma membrane part 2.87E-02 9.75E-03 
GO:0016043 Cellular component organization 3.42E-02 5.07E-03 
GO:0042060 Wound healing 3.68E-02 5.18E-02 
GO:0042221 Response to chemical stimulus 3.89E-02 3.02E-02 
GO:0009605 Response to external stimulus 4.10E-02 4.09E-09 
GO:0007155 Cell adhesion 4.10E-02 4.67E-02 
GO:0022610 Biological adhesion 4.17E-02 4.77E-02 
GO:0016485 Protein processing 4.88E-02 7.93E-02 
GO:0040011 Locomotion 4.88E-02 9.39E-04 
GO:0042127 Regulation of cell proliferation 5.01E-02 6.26E-02 
GO:0032879 Regulation of localization 5.34E-02 4.75E-05 
GO:0051604 Protein maturation 6.81E-02 9.50E-02 
GO:0030674 Protein binding, bridging 7.96E-02 3.08E-03 
GO:0045834 Positive regulation of lipid metabolic process 9.35E-02 6.88E-02 
 
 
 
 
 
 
 
 
 
 
 
  
Table 3. Differentially regulated gene interaction identified in Kegg pathways 
 
Kegg term Gene 
count 
-LogP Kegg term Gene 
count 
-LogP 
E
LT
 
Focal adhesion 
ECM-receptor interaction  
p53 signaling pathway 
Calcium signaling pathway 
12 
8 
6 
8 
2.78 
2.94 
1.99 
1.26 
ARVC 
Small cell lung cancer 
Oocyte meiosis 
5 
5 
5 
1.22 
1.10 
1.07 
D
a
m
s 
Natural killer cell mediated cytotoxicity 
Graft-versus-host disease 
Cytokine-cytokine receptor interaction 
Hematopoietic cell lineage 
Chemokine signaling pathway 
 Allograft rejection 
Type I diabetes mellitus 
Circadian rhythm 
Toll-like receptor signaling pathway 
Cytosolic DNA-sensing pathway 
20 
13 
21 
9 
12 
7 
7 
4 
8 
6 
11.81 
9.06 
7.33 
3.63 
3.04 
3.03 
2.84 
2.72 
2.47 
2.35 
Systemic lupus erythematosus 
ECM-receptor interaction 
NOD-like receptor signaling pathway 
Antigen processing and presentation 
p53 signaling pathway 
Autoimmune thyroid disease 
Oocyte meiosis 
T cell receptor signaling pathway 
Cell adhesion molecules (CAMs) 
7 
6 
5 
6 
5 
5 
6 
6 
7 
1.79 
1.62 
1.47 
1.47 
1.32 
1.27 
1.11 
1.07 
1.07 
O
ff
sp
ri
n
g
 
Focal adhesion 
Huntington's disease 
ECM-receptor interaction 
Oxidative phosphorylation 
Adherens junction 
Alzheimer's disease 
Ubiquitin mediated proteolysis 
Regulation of actin cytoskeleton 
Axon guidance 
Endocytosis 
Parkinson's disease 
Proteasome 
Viral myocarditis 
Valine, leucine and isoleucine degradation 
Small cell lung cancer 
Fc gamma R-mediated phagocytosis 
Spliceosome 
Insulin signalling pathway 
Pancreatic cancer 
Renal cell carcinoma 
Pyrimidine metabolism 
Vascular smooth muscle contraction 
Glutathione metabolism 
RNA degradation 
Tight junction 
Pathways in cancer 
Prostate cancer 
Phosphatidylinositol signalling system 
Neurotrophin signalling pathway 
Chronic myeloid leukemia  
Apoptosis 
110 
99 
49 
68 
44 
86 
68 
99 
64 
91 
64 
28 
47 
27 
43 
48 
58 
62 
36 
35 
45 
53 
27 
30 
58 
124 
41 
35 
55 
35 
39 
11.70 
9.65 
6.31 
5.96 
5.37 
5.09 
5.08 
5.00 
4.40 
4.36 
4.15 
3.73 
3.59 
3.46 
3.44 
3.40 
3.39 
3.03 
2.80 
2.73 
2.71 
2.45 
2.42 
2.37 
2.33 
2.30 
2.23 
2.13 
2.06 
2.02 
2.00 
Purine metabolism 
Nucleotide excision repair 
Glioma 
Non-small cell lung cancer 
RNA polymerase 
Colorectal cancer 
Propanoate metabolism 
SNARE interactions in vesicular transport 
mTOR signaling pathway 
Type II diabetes mellitus 
Leukocyte transendothelial migration 
B cell receptor signalling pathway 
Graft-versus-host disease 
p53 signalling pathway 
Long-term potentiation 
Hypertrophic cardiomyopathy (HCM) 
ErbB signalling pathway 
Cell adhesion molecules (CAMs) 
Glycosylphosphatidylinositol(GPI) 
-anchor biosynthesis 
Lysine degradation 
Gap junction 
Dilated cardiomyopathy 
 (ARVC) 
Aldosterone-regulated sodium reabsorption 
Natural killer cell mediated cytotoxicity 
Cell cycle 
Fatty acid biosynthesis 
GnRH signalling pathway 
Systemic lupus erythematosus 
64 
22 
30 
26 
15 
37 
16 
19 
25 
23 
48 
34 
26 
30 
30 
35 
36 
59 
13 
 
19 
35 
37 
31 
19 
47 
49 
5 
38 
40 
1.94 
1.91 
1.89 
1.83 
1.68 
1.60 
1.60 
1.55 
1.54 
1.50 
1.45 
1.41 
1.41 
1.41 
1.32 
1.32 
1.31 
1.26 
1.22 
 
1.21 
1.18 
1.16 
1.16 
1.11 
1.10 
1.09 
1.09 
1.04 
1.03 
 
The links between BP, CC and MF GO-terms processes were assessed utilising REVIGO and visualised in Cytoscape. ELT 
BPs showed several clusters of GO-terms (Figure 2). The large group GO-terms have been mapped by colour and listed 
with their associated GO-terms. One group classified under HDL particle remodelling included many cellular 
organisation processes and were heavily interlinked with cellular development processes. Response to inorganic 
substance formed many intragroup links but connected to HDL particle remodelling through a single node process of 
intracellular signal transduction. The majority of ELT CCs are interlinked cytoskeletal processes and extracellular 
structures and basolateral plasma membrane while MFs had interlinks between molecular binding, structural activity 
and kinase/transferase activity (Supplemental Table 2).  
 
  
Figure 2. ELT – BP interaction map. GO terms processed through REVIGO are visualised through Cytoscape. Node sizes 
are correlated to the ‘uniqueness’ value determined by REVIGO, where smaller nodes share more similarity with 
neighbouring GO terms. The red circle indicates bottleneck between the ‘Response to inorganic substance’s cluster 
and the larger and more heavily interlinked ‘Cell cycle and HDL remodelling’.  
The Dams BP associated REVIGO groupings showed a far more complex mapping (Figure 3). The large group GO-terms 
have been mapped by colour and listed with their associated GO-terms. There is a vast and heavily interconnected 
cluster of immune processes which also form multiple interactions with regulation of localisation. Smaller clusters of 
nuclear division and acylglycerol biosynthesis connect through to this massive cluster through single nodes of positive 
regulation of cellular component organisation and of lipid metabolism. There was a small CC interconnection with 
processes relating to the cell surface, extracellular space and protein/DNA interaction. MF interconnections between 
cytokine activity, Protein activity and Binding was also identified (Supplemental Table 3). 
Large similarities between the ELT and Dams exist in Cell cycle regulation and localization. While the ELT sees alteration 
to processes associated with response to inorganic substances on a cellular level, the Dams have a heavy immune 
response as a whole. The influence of this immune response can distract from the cellular mechanistic responses and 
is outlined in greater detail in the discussion. 
The Offspring REVIGO map of associated GO terms displayed a vast and highly interconnected network both intra- 
processes and inter-processes (Figure 4). The large group GO-terms have been mapped by colour and listed with their 
associated GO-terms. Translation and regulation of GTPases had the largest networks of GO terms in the BP map, while 
there was also a large number of regulatory changes in localization, cell-substrate adhesion and tube development 
and antigen processing. There was a large network of GO terms associated with the Mitochondrion cell projection and 
the basement membrane for the CC map and cytoskeletal binding, motor activity, ubiquitin-protein transferase activity 
and zinc iron binding in the MF map (Supplemental Table 4). 
 
  
Figure 3. Dams – BP interaction map. GO terms processed through REVIGO are visualised through Cytoscape. Node 
sizes are correlated to the ‘uniqueness’ value determined by REVIGO, where smaller nodes share more similarity with 
neighbouring GO terms. The red circle indicates bottleneck between the ‘Cell cycle and division’ cluster and the larger 
and more heavily interlinked ‘Immune system’. A bottle neck also connects ‘Acylglycerol biosynthesis’ pathways with 
‘Regulation of localisation’. 
 
 
 Figure 4. Offspring – BP interaction map. GO terms processed through REVIGO are visualised through Cytoscape. 
Node sizes are correlated to the ‘uniqueness’ value determined by REVIGO, where smaller nodes share more similarity 
with neighbouring GO terms. The highly interconnecting map does not have any bottlenecks in process interaction as 
seen in the ELT and Dams maps. The nodes in Grey show multiple smaller unlinked GO terms. 
 
 
Discussion 
Despite the high incidence and mortality that accompanies lung cancer and other pulmonary diseases, research 
funding remains disproportionately low. The additional pressures for refinement, reduction and replacement of animal 
testing is a driving need for alternative models that can more accurately represent human in vivo responses. This pilot 
study aimed at determining if the ELT (EpiAirway®) could provide this alternative without the obfuscating presence of 
an immune system. It was hoped the ELT would provide a reductionist view, useful for understanding initial, site-of 
impact and mechanics of the cellular interactions.  
Global transcriptomics pathway analysis allows analysis between individuals and also cross-species comparison. 
Requiring higher fold changes has often been used to filter out normal fluctuations in gene regulation. This 
accompanied with early FDR compensation can exclude many relevant genes. Indeed, some genes only require a 
minimal fluctuation in their regulation to have a profound effect and are highly regulated to avoid fluctuations (Raser 
and O’shea, 2005). Filtering genes with a lower threshold for fold change and allowing significance to be assessed in 
gene enrichment processes provides a more informative and reliable picture of global cellular response (Dalman et al. 
2011).   
Comparatively, fewer differentially expressed genes met the criteria for gene enrichment in the ELT model than in the 
Dams. The top differentially regulated genes and their functions were initially identified. In the ELT many of the 
upregulated genes had functions linked to cell cycle, while there was downregulation of cell adhesion and calcium 
homeostasis regulation. In the Dams there was heavy upregulation of immunoglobulins and immunity receptors and 
down regulation of fat regulation, detection and signalling pathways.  
These differences were observed (Table 1) for the ‘immune’ versus the ‘mechanical’ damage in the top 10 enriched 
terms,  where the top 10 in the Dams included immune response and response to external stimulus but the ELT is 
cellular structure. However, there were similarities, suggesting the same mechanical issues are occurring but they are 
hidden behind the overwhelming immune response. For example, common GO Terms included extra-cellular 
components (i.e. regions and spaces) and response to chemicals and external stimuli (Table 2). We also observed 
common Kegg pathways, such as the P53 signalling and ECM interaction pathways (Table 3). More pathways were 
exacerbated in Dams, again linked to the exceptional immune response, but cell cycle and cell adhesion responses 
were common. The inter-linking of these pathways demonstrated the inter-connectivity of stress responses and the 
comparative size of the immune response, but also common stress responses. Histologically, these broad similarities 
were observed, such as the loss of tight junctions, cytoskeleton differences and inflammatory responses associated 
with the exacerbated immune response. 
With regard to the additional analyses of the Offspring gene changes, though this research focus was the ELT versus 
Dam model comparison, the heavy alterations (i.e. 9,825 differentially expressed genes), nonetheless provides an 
interesting data-set. For example, GO Terms included those associated largely with translation, regulation of small 
GTPase-mediated signal transduction and regulation of localisation (Figure 4). Foetal development is a time when 
many genes are being turned on and off and the impacts of chemical exposures might well explain the significant 
number that was observed. Many of the known later-life impacts following pre-natal exposures to CS have been 
identified (Table 3), such as diabetes, Alzheimer’s and multiple cancer pathways (Doherty et al. 2009). 
Often times, animal models don’t recapitulate what is observed epidemiologically when it comes to cigarette smoke-
induced carcinogenesis.  However, a study by Hutt et al (2005; Carcinogenesis 26:11) used the B6C3F1 mouse strain 
(the same used in the present study) and found that lifetime exposure of female mice to MCS to 250 mg PM/m3 for 6 
h/d, 5 d/wk, induced an increased rate of focal alveolar hyperplasia, pulmonary adenomas, papillomas and 
adenocarcinomas. Versus unexposed control mice, those exposed to MCS had 10-fold increase in hyperplastic lesions, 
4.6-fold increase in adenomas, 7.25-fold increase in adenocarcinomas, and 5-fold increase in metastatic pulmonary 
adenocarcinoma. The selection of the mouse strain, i.e. the B6C3F1 hybrid strain, has been used in carcinogenesis assays 
by many researchers, as well as the National Toxicology Program (USA) due to its lung tumour response to certain 
chemicals like cigarette smoke and chemicals present in cigarette smoke. In addition, as reviewed by Pandiri (2015), 
“Meta-analysis of transcriptomic alterations in human and mouse lung tumours revealed significant similarities in lung 
cancer pathways in both species (Stearman et al. 2005; Bonner et al. 2004; Pandiri et al. 2012). These data indicate 
that mouse lung tumours are similar to human adenocarcinomas at the morphologic and molecular levels and that 
mouse lung tumours are relevant in evaluating carcinogenic hazards associated with environmental exposures.” 
In conclusion, the gene changes observed in the in vitro, 3-dimensional, cell culture model of the human bronchial 
epithelium mirrored the responses detected in the mouse model of pre-natal exposure to MCS. The ELT model could 
be utilised as the first step (i.e. before using animal models) to screening aerosolised compounds such as candidate 
respiratory drugs (Prytherch et al. 2011), combustion-derived air pollution (e.g. tobacco smoke (Sexton et al. 2008; 
Balharry et al. 2008; Sexton et al. 2011), diesel exhaust, fly ash particles and shipping emissions (Oder et al. 2015). The 
benefits of using alternative in vivo-like in vitro ALI models of the human lung are self-evident. The ELT model is both 
cost- and time-effective for toxicity testing of aerosolised and soluble compounds given that cell culture consumables 
are highly-affordable and permit rapid analyses. In comparison to animal models that are expensive due to costs of 
the animals and their maintenance, which could last for years, versus days and/or weeks for in vitro cell culturing 
practices (Prytherch and BéruBé, 2014). Finally, when considering the contentious ethical issues surrounding the use 
of animals for medical research, when using alternative systems like MatTek’s EpiAirway® platform, there is immediate 
impact for the 3Rs and human end-point data is acquired, negating the need to extrapolate data from animals into 
effects in man. 
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Supplemental Information 
 
Supplementary Table 1. Top 10 up and down differentially regulated genes in ELT, Dams and Offspring tissue after 
MCS exposure. 
 
 Up-regulated genes Down-regulated genes 
ELT Associated Gene 
ID 
P-value Fold change Associated Gene 
ID 
P-value Fold change 
C-FOS 8.85E-05 3.3303 FN1 2.16E-02 5.3997 
CD300A 1.29E-02 2.8970 SPARC 8.55E-03 3.9802 
SAG 9.15E-03 2.5003 CRNN 1.18E-02 3.0898 
MATN1 2.19E-03 2.2019 ADAM19 1.38E-03 2.9293 
CXCR4 4.92E-03 2.1926 GPC6 1.06E-02 2.7941 
SCG3 7.13E-04 2.1032 MMP12 6.47E-03 2.7559 
FRMD1 2.14E-02 2.0700 MMP2 1.32E-02 2.7509 
ELMOD1 3.15E-03 1.8967 SRPX 2.36E-04 2.5735 
HERC2P9 2.20E-03 1.8487 APOE 1.33E-02 2.5694 
GLYATL2 3.67E-02 1.8263 SPOCK1 1.24E-02 2.4189 
Dams IGHG 1.28E-03 10.0077 IGKV8 4.55E-02 12.4052 
IGKV5 5.29E-04 2.7783 RETN 4.47E-03 4.5923 
GZMB 2.29E-04 2.5938 TMEM45B 3.93E-03 4.5373 
IGHV1 1.35E-03 2.4647 CAR3 8.08E-04 4.2618 
MTFR2 3.14E-03 2.1057 ADIPOQ 2.43E-03 4.2096 
IL1B 2.90E-03 2.0812 CFD 7.08E-03 3.3732 
HIST1HiB 4.13E-02 1.9907 TFF2 6.26E-03 2.7266 
KLRA17 6.94E-03 1.9576 THRSP 4.08E-03 2.4456 
ARNTL 1.08E-03 1.9509 PLIN1 1.07E-02 2.3777 
FEFV 7.98E-04 1.9452 MUC5B 3.06E-02 2.3440 
Offspring H2AB1 0.017866 17.57977 BEST1 8.17E-07 10.84912 
H2Q7 0.016136 15.42327 MBNL1 0.011763 10.23817 
TRMT61 0.0028 8.509253 AHDC1 8.64E-06 7.887322 
LY6D 0.010242 6.925174 BAIAP2L1 2.17E-05 7.718487 
STRA8 0.002144 6.818615 KCNQ1OT1 9.31E-06 7.359658 
H2DMB2 9.13E-04 6.113622 TNS1 5.16E-06 7.111162 
APOL7C 0.015917 5.175049 TJPs 2.51E-06 6.984259 
IFI44L 0.001521 5.093131 AGAP1 7.56E-06 6.975762 
HBB-BT 0.028783 4.819223 PITPNC1 0.00172 6.867369 
IKZF4 2.50E-04 4.78618 ZFHX3 7.63E-06 6.528332 
 
Supplemental Table 2. Some of the larger groups of REVIGO linked GO terms of CC and MF processes for the ELT. 
 
CC-Processes Linked GO terms MF-Processes Linked GO terms 
Extracellular region part GO:0044421, GO:0005578, 
GO:0034361, GO:0005615, 
GO:0031012, GO:0005576. 
Molecular binding.
 
 
GO:0001948, GO:0030674, 
GO:0003779, GO:0008092, 
GO:0008289, GO:0005488, 
GO:0005509, GO:0005543. 
Basolateral plasma membrane. 
 
GO:0016323, GO:0044459, 
GO:0005581, GO:0043234. 
Structural molecule
 
activity.
 
 
GO:0003777, GO:0008330, 
GO:0016817, GO:0017111, 
GO:0008233, GO:0003774, 
GO:0008237, GO:0004222, 
GO:0005198, GO:0005200, 
GO:0005201. 
Cytoskeleton. 
 
GO:0005856, GO:0043005, 
GO:0044463, GO:0005929, 
GO:0044449, GO:0044441, 
GO:0043292, GO:0043228, 
GO:0044430, GO:0043232, 
GO:0014069, GO:0001533, 
GO:0042995, GO:0070161, 
GO:0019861, GO:0030315. 
Kinase, hydrolase and 
transferase activity.
 
 
GO:0008603, GO:0019207, 
GO:0047961, GO:0019205, 
GO:0016787. 
 
 
 Supplemental Table 3. Some of the larger groups of REVIGO linked GO terms of CC and MF processes for the Dams. 
CC-Processes Linked GO terms MF-Processes Linked GO terms 
 Chromosome, centromeric 
region and protein DNA 
interaction.
 
 
GO:0005694, GO:0000775, 
GO:0032133, GO:0030141, 
GO:0019814, GO:0032993. 
Protein activity.
 
 
GO:0004144, GO:0003924, 
GO:0060089, GO:0004872, 
GO:0004869, GO:0004950, 
GO:0004896, GO:0004871, 
GO:0015144, GO:0005384, 
GO:0015291, GO:0015294. 
Cell surface.
 
 
GO:0009897, GO:0005887, 
GO:0005886, GO:0044459, 
GO:0009986. 
Cytokine activity.
 
 
GO:0008009, GO:0019956, 
GO:0005125, GO:0019955, 
GO:0001664, GO:0043515, 
GO:0005102, GO:0005070. 
Extracellular space.
 
 
GO:0044421, GO:0044421, 
GO:0005615, GO:0042571, 
GO:0005576. 
Binding.
 
 
GO:0001872, GO:0003823, 
GO:0005488, GO:0060090, 
GO:0030246, GO:0005515, 
GO:0001871. 
 
 
Supplemental Table 4. Some of the larger groups of REVIGO linked GO terms of CC and MF processes for the 
Offspring. 
CC-Processes Linked GO terms MF-Processes Linked GO terms 
 Mitochondrion.
 
 
GO:0015629, GO:0032432 
GO:0042641, GO:0016327, GO:0005938, 
GO:0044448, GO:0005832, GO:0044427, 
GO:0005694, GO:0005905, GO:0005581, 
GO:0043292, GO:0005737, GO:0016023, 
GO:0000932, GO:0044444, GO:0009898, 
GO:0005856, GO:0005829, GO:0044445, 
GO:0022626, GO:0022627, GO:0030286, 
GO:0005793, GO:0000178, GO:0005794, 
GO:0000792, GO:0043232, GO:0043229, 
GO:0044424, GO:0005770, GO:0005811, 
GO:0030117, GO:0034708, GO:0042613, 
GO:0042611, GO:0042579, GO:0044455, 
GO:0044429, GO:0005746, GO:0005739, 
GO:0032982, GO:0016460, GO:0043228, 
GO:0005720, GO:0031981, GO:0044428, 
GO:0005634, GO:0000313, GO:0031090, 
GO:0044422, GO:0048471, GO:0005777, 
GO:0046930, GO:0000502, GO:0005839, 
GO:0043234, GO:0045259, GO:0016469, 
GO:0030529, GO:0030880, GO:0030017, 
GO:0000803, GO:0015935, GO:0001725, 
GO:0042825, GO:0000151, GO:0005774, 
GO:0005773, GO:0031982. 
Cytoskeletal protein 
binding
 
 
GO:0003779, GO:0003785, GO:0008013, 
GO:0005516, GO:0051087, GO:0008092, 
GO:0019899, GO:0051020, GO:0051427, 
GO:0042802, GO:0043560, GO:0005178, 
GO:0035257, GO:0048407, GO:0030674, 
GO:0032403, GO:0046983, GO:0019904, 
GO:0046982, GO:0017048, GO:0017124, 
GO:0046332, GO:0008134, GO:0051082. 
Motor activity GO:0004559, GO:0042623, GO:0003689, 
GO:0004521, GO:0016817, GO:0016820, 
GO:0016788, GO:0015923, GO:0000146, 
GO:0003774, GO:0016791, GO:0034595, 
GO:0042578, GO:0033170, GO:0004540, 
GO:0004298, GO:0070003. 
Ubiquitin-protein 
transferase activity.
 
 
GO:0019200, GO:0003899, GO:0004364, 
GO:0004402, GO:0042054, GO:0004468,  
GO:0016278, GO:0004709, GO:0008168, 
GO:0008080, GO:0019205, GO:0004550,  
GO:0016773, GO:0016776, GO:0004672, 
GO:0008276, GO:0004674, GO:0004713,  
GO:0034062, GO:0016765, GO:0016741, 
GO:0016772, GO:0004714, GO:0004842. 
 
Cell projection 
part.
 
GO:0044463, GO:0005929, GO:0030027, 
GO:0043005. 
Zinc ion binding.
 
 
GO:0005524, GO:0043169, GO:0019992, 
GO:0005525, GO:0019001, GO:0043167, 
GO:0000287, GO:0030145, GO:0046872, 
GO:0003676, GO:0035091, GO:0017076, 
GO:0046914, GO:0008270. 
Basement 
membrane. 
 
 
GO:0005604, GO:0030935. 
 
